Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $560.13M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 2.78M
Average 4.86M
WVE EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Wave Life Sciences Ltd.NASDAQ: WVE
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$23.78M, compared with -$44.71M a year earlier. Trailing-twelve-month EBITDA was -$174.59M.
Context
- EBITDA amounted to 457.6% of revenue in FY2025, up 376.0 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 15 analysts of -$165.57M (+15.3%) for the fiscal year ending Dec 2026, a step up from the -121.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.78M+53.3% QoQ
- Last fiscal yearDec 2025
- -$195.53M-121.3% YoY
- LTMMar 2026
- -$174.59M-68.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +46.8% | -21.9% | -68.7 pp |
| 1 year | -121.3% | +15.3% | +136.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (195.53M) USD
- Year-over-year change
- -121.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (195.53M) | -121.3% |
| FY2024 | 2024-12-31 | (88.35M) | -80.4% |
| FY2023 | 2023-12-31 | (48.98M) | +67.6% |
| FY2022 | 2022-12-31 | (151.03M) | -34.1% |
| FY2021 | 2021-12-31 | (112.61M) | — |
EBITDA vs competitors
How WVE compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -68.4% is the 7th highest of 10, against a peer median of -44.4%.
- EBITDA amounts to 243.2% of revenue for WVE, versus a peer median of 148.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.15B USD | +773.6% | — | 24.0% | |
| LTM Mar 2026 | $124.95M USD | +217.3% | — | 5.7% | |
| LTM Mar 2026 | -€42.88M EUR | -67.7% | — | 319.0% | |
| LTM Mar 2026 | -$53.46M USD | -44.4% | — | — | |
| LTM Mar 2026 | -$67.53M USD | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$78.13M USD | — | — | 8478.5% | |
| LTM Mar 2026 | -$164.11M USD | -405.9% | — | 511.5% | |
| LTM Mar 2026 | -$174.59M USD | -68.4% | — | 243.2% | |
| LTM Mar 2026 | -$384.61M USD | +25.4% | — | 581.9% | |
| LTM Sep 2026 | -$473.54M USD | -208.3% | — | 49.3% | |
| LTM Sep 2026 | -$603.58M USD | -466.2% | — | 133.9% | |
| Peer median (excluding WVE) | — | -44.4% | — | 148.9% | |
Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 40.96M | 3.65M | 113.31M | 108.3M | 42.73M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 8.85M |
| Gross Profit | 40.96M | 3.65M | 113.31M | 108.3M | 33.88M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 79.3% |
| Research & Development | 121.88M | 115.86M | 130.01M | 159.68M | 182.78M |
| Selling, General & Admin | 46.11M | 50.51M | 51.29M | 59.02M | 75.33M |
| Operating Expenses | 167.98M | 166.37M | 181.3M | 218.71M | 249.26M |
| Depreciation & Amortization | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| EBITDA | (112.61M) | (151.03M) | (48.98M) | (88.35M) | (195.53M) |
| EBITDA Margin | -274.9% | -4138.9% | -43.2% | -81.6% | -457.6% |
| Operating Income | (127.02M) | (162.72M) | (68M) | (110.4M) | (215.38M) |
| Operating Margin | -310.1% | -4459.3% | -60.0% | -101.9% | -504.1% |
| Interest Income | 30K | 0 | 0 | 0 | 10.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.57M | 1.58M | 9.81M | 13.4M | 11.01M |
| Income Before Tax | (122.45M) | (161.14M) | (58.19M) | (97.01M) | (204.38M) |
| Pre-Tax Margin | -298.9% | -4416.1% | -51.4% | -89.6% | -478.3% |
| Income Tax Expense | (204K) | 681K | (677K) | 0 | 0 |
| Net Income | (122.25M) | (161.82M) | (57.51M) | (97.01M) | (204.38M) |
| Net Margin | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
| EPS (Basic) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| EPS (Diluted) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| Weighted Avg Shares | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
| Weighted Avg Shares (Diluted) | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
Wave Life Sciences Ltd.
NASDAQ:WVE
Intrinsic Alpha fair value
Locked
Current Price
$2.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.